Cannabis and Eczema
What the evidence actually says about cannabinoids, topical hemp products, and atopic dermatitis — separating marketing from science.
Eczema is one of the most heavily marketed indications for CBD and hemp products, and the science doesn't really back the hype. Hemp seed oil is a decent moisturizer — basically a fatty acid emollient — and that's the strongest claim you can honestly make. Topical CBD for eczema has almost no controlled human trial data. The endocannabinoid system is genuinely involved in skin biology, but 'involved in' is not the same as 'CBD cream cures your flare.' Standard treatments still work better.
Not medical advice
This article is for educational purposes and is not medical advice. Eczema has many subtypes and triggers, and severe eczema can become infected or signal other immune issues. If you have moderate-to-severe eczema, talk to a dermatologist before substituting cannabis-derived products for evidence-based treatment. Nothing here should be read as a recommendation to stop prescribed medication.
Plain-language summary
Eczema, most often atopic dermatitis, is a chronic inflammatory skin condition driven by a leaky skin barrier and an overactive type-2 immune response [1]. It itches, it flares, and it's miserable.
Cannabis and hemp products are heavily marketed for eczema, especially CBD creams and hemp seed oil lotions. Here's the honest picture:
- Hemp seed oil (pressed from cannabis seeds, contains essentially no cannabinoids) is a reasonable emollient. It's high in linoleic and alpha-linolenic acid, and one small randomized crossover trial reported improvement in atopic dermatitis symptoms with dietary hemp seed oil [2]. Weak / limited
- Topical CBD has a plausible biological story — the skin has cannabinoid receptors and the endocannabinoid system regulates inflammation and keratinocyte behavior [3] — but almost no controlled human trial data specifically in eczema. Weak / limited
- Smoking or eating cannabis to treat eczema has no real evidence behind it. No data
- Cannabis itself can cause skin reactions in a minority of users (contact dermatitis, allergy) [4]. Strong evidence
Standard treatments — emollients, topical corticosteroids, topical calcineurin inhibitors, and for severe cases, dupilumab or JAK inhibitors — are far better studied and far more effective [1].
What probably works
Hemp seed oil as a moisturizer. Any bland emollient helps eczema by restoring the skin barrier; this is a cornerstone of guideline-based care [1]. Hemp seed oil is rich in polyunsaturated fatty acids and works as a topical emollient about as well as other plant oils. A 2005 crossover trial in 20 patients found that 8 weeks of dietary hemp seed oil reduced dryness, itchiness, and topical medication use compared to olive oil [2]. Weak / limited
The likely mechanism is mundane: it's a fatty acid source that supports barrier lipids. You don't need cannabinoids for this effect, and you should not pay cannabis-brand prices for what is essentially a seed oil.
What might work
Topical CBD and other cannabinoids. The skin expresses CB1, CB2, and several non-classical cannabinoid-sensitive receptors (TRPV1, PPAR-γ), and endocannabinoids modulate keratinocyte proliferation, sebocyte activity, and immune cell behavior [3]. In vitro and animal studies show that cannabinoids can dampen inflammation and itch signaling [5]. Weak / limited
Human data is thin. A few small open-label or observational reports describe symptom improvement with topical cannabinoid creams in atopic and other dermatoses, but these lack blinding, control arms, or adequate sample sizes [6]. Weak / limited
PEA (palmitoylethanolamide), a fatty acid amide related to the endocannabinoid system (not from cannabis), has slightly better data. A multicenter study of a PEA-containing cream reported reduced itch and improved skin in atopic dermatitis [7]. PEA is sometimes lumped in with 'cannabinoid' marketing, but technically it's an endogenous lipid mediator. Weak / limited
Net read: biologically plausible, commercially overhyped, clinically underproven.
What doesn't work or has weak evidence
Smoking cannabis to treat eczema. No controlled evidence. Smoke is a known skin irritant and inhaled cannabis is associated with worse outcomes in other inflammatory conditions. No data
Oral CBD specifically for eczema. No published randomized controlled trials in atopic dermatitis as of this writing. Generalizing from CBD's anti-inflammatory effects in other settings is not enough. No data
'Indica vs sativa' for skin conditions. The indica/sativa split doesn't reliably predict chemistry or effects, and there's zero evidence one 'type' helps eczema more than another. This is marketing folklore. No data
High-THC topicals as a specific eczema treatment. THC has anti-inflammatory effects in lab models, but human eczema data is absent. Topicals also don't produce systemic THC levels meaningful for immune modulation [8]. Weak / limited
What we don't know
- Whether topical CBD at clinically meaningful concentrations outperforms a vehicle cream in a properly blinded RCT for atopic dermatitis.
- Whether oral cannabinoids modulate the type-2 immune axis (IL-4, IL-13) enough to matter for eczema patients.
- Optimal concentration, vehicle, or dosing schedule for any topical cannabinoid.
- Whether chronic cannabis use changes eczema trajectory in either direction.
- Interactions between cannabinoids and biologics like dupilumab.
This is a field where the marketing has wildly outrun the science.
Comparison with standard treatments
Standard atopic dermatitis care, per AAD and EuroGuiDerm guidelines [1]:
- Emollients (daily, including hemp seed oil if you like) — foundation of treatment.
- Topical corticosteroids — first-line for flares; decades of evidence; potency matched to body site and severity.
- Topical calcineurin inhibitors (tacrolimus, pimecrolimus) — steroid-sparing, good for face and folds.
- Topical JAK inhibitors (ruxolitinib) — newer, effective, expensive.
- Phototherapy — for moderate disease.
- Systemic therapy — dupilumab (anti-IL-4Rα), tralokinumab, oral JAK inhibitors for moderate-to-severe disease; these are genuinely transformative for many patients.
No cannabis-derived product has been shown in a high-quality trial to match even mid-potency topical steroids for flare control. If a CBD cream helps you and it's not replacing necessary treatment, fine. But it is not a substitute for the things that actually work.
Risks and considerations
Cannabis allergy and contact dermatitis. Cannabis sativa contains allergens (notably the non-specific lipid transfer protein Can s 3) that can cause IgE-mediated reactions, contact urticaria, and allergic contact dermatitis [4]. People with eczema already have a compromised barrier and are more prone to contact sensitization in general. Strong evidence
Product quality. The CBD and hemp topical market is poorly regulated. FDA testing has repeatedly found products that don't match label claims, contain unexpected THC, or are contaminated with heavy metals or pesticides [9]. Applying contaminated products to broken eczematous skin is a bad idea.
Drug interactions. Topical absorption of CBD is low, but oral CBD inhibits CYP3A4 and CYP2C19 and can interact with medications including some eczema-relevant drugs [10]. Strong evidence
Cost and opportunity cost. Cannabis-branded skin products are often expensive. The same money spent on a ceramide-based moisturizer plus a prescription topical will almost certainly deliver more relief.
Pediatric use. Eczema commonly affects children. There is essentially no safety data for topical CBD in pediatric eczema. Stick to guideline-based care for kids.
Bottom line
Use hemp seed oil as a moisturizer if you like it — it works fine as an emollient. Don't expect topical CBD to do much beyond what its base cream does, and don't pay a premium for it. Don't smoke weed expecting your eczema to improve. See a dermatologist for moderate-to-severe disease; the modern toolkit (especially dupilumab and topical JAK inhibitors) is genuinely good. The endocannabinoid system in skin is a real and interesting research target, but as of today the consumer market is selling promises the science hasn't earned.
Sources
- Peer-reviewed Wollenberg A, et al. (2022). European guideline (EuroGuiDerm) on atopic eczema – part I and II. Journal of the European Academy of Dermatology and Venereology, 36(9-10).
- Peer-reviewed Callaway J, Schwab U, Harvima I, et al. (2005). Efficacy of dietary hempseed oil in patients with atopic dermatitis. Journal of Dermatological Treatment, 16(2), 87-94.
- Peer-reviewed Bíró T, Tóth BI, Haskó G, Paus R, Pacher P (2009). The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends in Pharmacological Sciences, 30(8), 411-420.
- Peer-reviewed Decuyper II, Van Gasse AL, Cop N, et al. (2017). Cannabis sativa allergy: looking through the fog. Allergy, 72(2), 201-206.
- Peer-reviewed Tóth KF, Ádám D, Bíró T, Oláh A (2019). Cannabinoid signaling in the skin: therapeutic potential of the 'c(ut)annabinoid' system. Molecules, 24(5), 918.
- Peer-reviewed Eagleston LRM, Kalani NK, Patel RR, et al. (2018). Cannabinoids in dermatology: a scoping review. Dermatology Online Journal, 24(6). ↗
- Peer-reviewed Eberlein B, Eicke C, Reinhardt HW, Ring J (2008). Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). Journal of the European Academy of Dermatology and Venereology, 22(1), 73-82.
- Peer-reviewed Stinchcomb AL, Valiveti S, Hammell DC, Ramsey DR (2004). Human skin permeation of Δ8-tetrahydrocannabinol, cannabidiol and cannabinol. Journal of Pharmacy and Pharmacology, 56(3), 291-297.
- Government U.S. Food and Drug Administration (2021). FDA warning letters and test results for cannabidiol-related products. ↗
- Peer-reviewed Brown JD, Winterstein AG (2019). Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. Journal of Clinical Medicine, 8(7), 989.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis and Psoriasis — What the evidence actually says about using cannabis, CBD, and THC for psoriasis — separat...